Health Canada recently published two guidance documents, effective May 23, 2018, that address the reporting of adverse reactions to marketed health products (excluding blood and blood components and cells, tissues and organs). First, Reporting Adverse Reactions to Marketed Health Products provides assistance on reporting adverse reactions to marketed health products including good case management practices. Second, Preparing and Submitting Summary Reports for Marketed Drugs and Natural Health Products addresses the format and content of annual summary reports (ASRs) and issue-related summary reports (IRSRs), as well as procedures for submission of these reports to Health Canada.
Related Publications & Articles
-
Health Canada releases its Statistical Report 2024/2025 for PMNOC Regulations, data protection and CSPs
On July 25, 2025, the Office of Patented Medicines and Liaison of Health Canada released its Statistical Report 2024/2025 for the Patented Medicines (Notice of Compliance) Regulations, Data Protection...Read More -
Health Canada aims to reduce red tape by increasing international collaboration, alignment and reliance
In July 2025, the Government of Canada launched a “Red Tape Review” across all federal departments to modernize regulatory frameworks and support economic growth.Read More -
Medical devices updates: new Health Canada guidance for determining medical device application type and Medical Devices Directorate performance reports released
In August 2025, Health Canada released the Guidance for determining medical device application type.Read More